Related Experiment Video
Updated: Jul 23, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Risk-benefit analysis of warfarin therapy in Hancock mitral valve replacement
Summary
Warfarin therapy after Hancock porcine xenograft mitral valve replacement increased bleeding risks but showed no significant difference in thromboembolic complications. Further research is needed to confirm these findings.
Area of Science:
- Cardiovascular Surgery
- Thrombosis and Hemostasis
Background:
- Mitral valve replacement with the Hancock porcine xenograft requires careful management of thromboembolic and bleeding risks.
- Anticoagulant therapy is commonly used but its efficacy and safety profile need continuous evaluation.
Purpose of the Study:
- To analyze thromboembolic and major bleeding complications in patients undergoing mitral valve replacement with the Hancock porcine xenograft.
- To compare outcomes between patients treated with warfarin, aspirin, no anticoagulants, or a combination.
Main Methods:
- A nonrandomized study of 124 patients with Hancock porcine xenograft mitral valves.
- Patients were divided into four groups: warfarin, aspirin, no anticoagulants, and warfarin plus aspirin.
- Follow-up averaged 3.03 years, assessing thromboembolic and bleeding events.
Main Results:
- No significant difference in embolic rates was observed across treatment groups.
- Warfarin therapy was associated with a significant increase in major bleeding episodes, including two deaths.
- Embolic rates were 2.97 and 3.25 per 100 patient-years for combined warfarin and aspirin/no anticoagulant groups, respectively.
Conclusions:
- Long-term warfarin therapy increases bleeding risk in patients with Hancock porcine xenograft mitral valves.
- Warfarin may not significantly impact the incidence of thromboembolism from this specific prosthetic valve.
- Larger studies are necessary to definitively confirm the influence of anticoagulation on thromboembolic risk.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...